The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.c

Pleural thickening - Fibrothorax

Publications

Erwteman TM, Braat MC, van Aken WG

Interstitial pulmonary fibrosis: a new side effect of practolol.

British medical journal 1977 Jul 30;2;297-8 — 1977 Jul 30 — 297-8

Hall DR, Morrison JB, Edwards FR

Pleural fibrosis after practolol therapy.

Thorax 1978 Dec;33;822-4 — 1978 Dec — 822-4

Marshall AJ, Eltringham WK, Barritt DW, Davies JD, Griffiths DA, Jackson LK, Laszlo G, Read AE

Respiratory disease associated with practolol therapy.

Lancet (London, England) 1977 Dec 17;2;1254-7 — 1977 Dec 17 — 1254-7